Intas Pharmaceuticals
Ahmedabad, India· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A leading global pharmaceutical company developing and manufacturing generics, biosimilars, and complex injectables across oncology, cardiovascular, and neuroscience.
OncologyCardiovascularNeuroscienceImmunologyInfectious Disease
Technology Platform
Proprietary Nanoaqualip™ technology for formulating drug products with improved bioavailability and reduced toxicity, and a strong in-house biosimilar development platform aligned with EU/US guidelines.
Opportunities
Significant growth opportunity lies in expanding its biosimilar portfolio in regulated markets (US/EU) and successfully commercializing its proprietary NCE for oncology/neurodegenerative diseases, moving up the value chain from generics.
Risk Factors
Key risks include intense pricing pressure and competition in the global generics and biosimilar markets, regulatory hurdles for complex product approvals, and execution risk in advancing its novel NCE pipeline.
Competitive Landscape
Competes with large global generics and biosimilar players like Sun Pharma, Dr. Reddy's, and Biocon. Differentiation is driven by its vertical integration, focus on complex injectables and biosimilars, proprietary Nanoaqualip™ delivery technology, and strong commercial footprint in over 85 countries.